ECP 2022 Final Programme

Sunday, 4 Sept 167 ECP 2022 Basel 006 13:55–14:05 Biomarker-Driven Therapies Beyond Immuno-Oncology: What Oncologists Need to Know From a Pathology Report Aristotelis Bamias, Greece 007 14:05–14:15 The Uropathologist Perspective: Diagnostic Biomarkers for Bladder Cancer Eva Compérat, Austria 008 14:15–14:30 Audience Q&A to Follow Presentations Reinhard Büttner, Germany LS-04 Industry Symposium 13:00–14:30 Boston Exploration of actionable biomarkers in determining eligibility for immunotherapy (MSD) Chair: Lukas Bubendorf, Switzerland 001 13:00–13:05 Welcome and introductions Lukas Bubendorf, Switzerland 002 13:05–13:25 Keeping up with the evolving PD-L1 landscape Arndt Hartmann, Germany 003 13:25–13:45 Panel discussion: New kids on the block - Recent PD-L1 indications and practical considerations for scoring Faculty and Lukas Bubendorf, Switzerland 004 13:45–13:55 Q&A Faculty 005 13:55–14:15 The increasing relevance of MSI/MMR testing in oncology Paula Borralho Nunes, Portugal 006 14:15–14:25 Q&A Faculty 007 14:25–14:30 Closing Remarks Lukas Bubendorf, Switzerland LS-05 Industry Symposium 13:00–14:30 Delhi Rethinking KRAS : From emerging to actionable biomarker in NSCLC (Amgen) Chair: Frédérique Penault-Llorca, France 001 13:00–13:10 Welcome and introduction Frédérique Penault-Llorca, France 002 13:10–13:25 KRAS therapy today: Approvals and pipeline developments for KRAS G12C Alfredo Addeo, Switzerland 003 13:25–13:45 Actioning KRAS G12C in NSCLC: Who, when and how to test? Frédérique Penault-Llorca, France 004 13:45–14:00 Targeting KRAS G12C : Clinicopathologic diversity, co-mutations and resistance Johan Botling, Sweden 005 14:00–14:25 Overcoming diagnostic challenges: Panel discussion and Q&A All incl. Sven Perner, Germany 006 14:25–14:30 Summary Frédérique Penault-Llorca, France LS-06 Industry Symposium 13:00–14:30 Shanghai Transformation for Next-Generation Digi- tal Pathology (3D HISTECH) Chair: Béla Molnár, Hungary 001 ”Bits to bedside”: the Nijmegen experience in digital and computational pathology Katrien Grünberg, The Netherlands 002 Whole Tissue Imaging & Whole Block Imaging Essentials Yukako Yagi, USA 003 Next-generation tissue microarrays (ngTMA®): from scientific discoveries to clinical practice Paulina Brönnimann, Switzerland Industry Symposia